Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT05093959 Not yet recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction Pilot Study

Met-PEFpilot
Start date: November 2021
Phase: Phase 2
Study type: Interventional

Met-PEF will be a randomized, double-blind, placebo-controlled trial to examine the effects of 20 weeks of 1500 mg/day of metformin on physical function, quality of life (QOL), microbiome diversity, leaky gut, and systemic inflammation in patients with 20 older patients with heart failure with preserved ejection fraction (HFpEF).

NCT ID: NCT05093933 Not yet recruiting - Clinical trials for Chronic Heart Failure With Reduced Ejection Fraction

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

VICTOR
Start date: November 15, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.

NCT ID: NCT05093621 Recruiting - Heart Failure Clinical Trials

Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure

TFO
Start date: February 8, 2021
Phase: Phase 3
Study type: Interventional

The study is designed to be a prospective, randomized study is to compare the effectiveness of two standard of care loop diuretics (furosemide versus torsemide) on clinical outcomes among patients currently on a stable dose of loop diuretics.

NCT ID: NCT05091710 Not yet recruiting - Heart Failure Clinical Trials

Haiti Community Health Workers (CHW) Adaptation

Start date: December 2021
Phase: N/A
Study type: Interventional

Evidence-based interventions to improve linkage and outcomes for heart failure (HF) patients requires input from stakeholders: patients, community health workers (CHWs), healthcare staff, and health system administrators. In this research the investigators will assess a CHW intervention designed to improve linkage to care for HF patients. This intervention was systematically adapted for use in rural Haiti in a prior study using the Assessment, Decisions, Administration, Production, Topical Experts, Integration, Training staff, Testing (ADAPT-ITT) framework. The ADAPT-ITT framework provides 8 sequential phases to adapt interventions and programs to new target audiences. It has been applied successfully to the adaptation of several interventions for HIV among under-resourced communities leading to randomized clinical trials. With the first 6 steps of the ADAPT-ITT framework completed in a prior study, this protocol outlines the training and testing of the adapted CHW intervention. In addition to assessing the feasibility, appropriateness, and acceptability of the adapted intervention through participants' feedback, the investigators will assess its efficacy in improving HF outcomes. The proposed intervention is targeted at both the patient domain - through improved peer support - and health system domain - by improving health system navigation.

NCT ID: NCT05090930 Recruiting - Sepsis Clinical Trials

Innovative Technologies for the Treatment of Pulmonary and Heart Failure

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The purpose of the program. Formulation of new treatments for heart and pulmonary failure through using organ-replacing technologies. Formulation of a clinical protocol and implementation of treatment methods into clinical practice heart and pulmonary failure using organ-replacing technologies. New methods were created for rehabilitating the function of affected organs after implantation of the LVAD, a total artificial heart, an extracorporeal life-sustaining system will be of great importance, both for Kazakhstan and for states with similar problems of donor organ deficiency, will also improve the effectiveness of surgical treatment and reduce the level of complications and mortality of patients on the extracorporeal life-sustaining system and septic patients.

NCT ID: NCT05090202 Not yet recruiting - Clinical trials for Chronic Heart Failure

Prediabetes and Newly Diagnosed Diabetes in Chronic Heart Failure

Start date: October 18, 2021
Phase:
Study type: Observational [Patient Registry]

The aim the study is to determine the prevalence of prediabetic dysglycemia and newly diagnosed diabetes among individuals with CHF(chronic heart failure) in sohag university hospital patients .

NCT ID: NCT05090137 Not yet recruiting - Heart Failure Clinical Trials

Quantifying Congestion by Ultrasound

QUEST-HF
Start date: November 2021
Phase: N/A
Study type: Interventional

The investigators will determine the feasibility of identifying and quantifying changes in interstitial and intravascular congestion by imaging in participants with heart failure. The investigators will either continue or temporarily suspend both loop diuretics and mineralo-corticoid antagonists (MRA) for 48 hours in participants with heart failure that is both stable and mild and compare measurements of interstitial (B-lines) and intra-vascular fluids (IVC and JV diameter and renal venous flow) by ultrasound and, in a subset of participants without contra-indications, by cardiac MRI.

NCT ID: NCT05089539 Not yet recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF

ARNICFH
Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

The effectively therapeutic approaches for Heart failure with preserved ejection fraction (HFpEF) remain limited. The PARAGON-HF trial found that Angiotensin Receptor-Neprilysin Inhibition (ARNI) has potential benefits for the management of HFpEF. Nevertheless, the role of ARNI in cardiac fibrosis in HFpEF are still unclear. We will conduct a prospective randomized controlled trial to evaluate the effect of ARNI on cardiac fibrosis in patients with HFpEF by cardiac magnetic resonance (CMR).

NCT ID: NCT05089279 Not yet recruiting - Clinical trials for Chronic Heart Failure

Study to Evaluate the Safety and Pharmacokinetics of CKD-349

Start date: October 20, 2021
Phase: Phase 1
Study type: Interventional

Study to Evaluate the Safety and Pharmacokinetics of CKD-349

NCT ID: NCT05089162 Not yet recruiting - Clinical trials for Chronic Heart Failure With Reduced Ventricular Ejection Fraction

CHF-COV Reduced (Chronic Heart Failure With Reduced Ejection Fraction - COngestion eValuation)

CHF-COVReduced
Start date: December 20, 2021
Phase: N/A
Study type: Interventional

Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation. The main objective of the CHF-COVReduced study is to identify congestion markers (clinical, biological and ultrasound) in day hospitalization for the monitoring of chronic HF with reduced left ventricular ejection fraction that are associated with the risk of all-cause death, hospitalization for acute HF or IV diuretics injection in a day hospital.